Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).
AMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.
AMD is currently treated by injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drug as eye drops.
Laboratory research, published last year in Investigative Ophthalmology & Visual Science (IOVS), showed that these eye drops have a similar therapeutic effect as the injected drug in rats. Now the Birmingham scientists have taken their research one step further by investigating the effect of the eye drops in the larger eyes of rabbits and pigs, which are more similar to human eyes.
This latest study, also published in IOVS, demonstrates that the eye drops can deliver a therapeutically effective amount of the drugs to the retina of the larger mammalian eye.
The technology behind the eye drops is a cell-penetrating peptide that can deliver the drug to the retina (the back of the eye). The scientists’ pending patents for the eye drops are now owned by US-based company, Macregen Inc, and a team of Birmingham researchers is working with the company to develop a novel range of therapies for AMD and other eye diseases.
The combined team is now expediting proof of concept studies to confirm the validity of the therapeutic approach. Clinical trials will be imminent once these studies are completed, and could start as early as spring 2019.
Dr de Cogan said: “For several years, our team has focused on the challenge of delivering drugs to the back of the eye.
“From the outset, we realised that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.
“Now we have shown that the eye drops work in the larger mammalian eye, and we welcome the commercial investment and expertise from Macregen so we can deliver a structured research and development programme that should bring concrete benefits to people with AMD and eye diseases.”
Professor Robert Scott, Consultant Ophthalmologist and Honorary Professor of Ophthalmology at University of Birmingham, commented: “Cell-penetrating peptides will drive the next generation of treatment for people with AMD.
“They will be transformative for patients who currently have to organise their lives around monthly clinic visits for uncomfortable intraocular injections, who will in the future have the convenience of self-administering their medical treatment.”
Keith Roizman, Founder, Executive Chairman, and Chief Technology Officer of Macregen, said: “Macregen and the company’s prospective strategic partners and licensees are expected to make significant investments in laboratory proof of concept studies, the subsequent research and development programmes and clinical trials.
“We will also pursue the necessary and required regulatory programmes to make these eye drops available to patients.”
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Study shows importance of targeted antibody treatment for patients with wet macular degenerationon November 15, 2019 at 10:59 am
Wet age-related macular degeneration (wAMD) is one of the leading causes of blindness in the U.S. Breakthrough treatments come with a steep price tag and treatment burden for the patient, but a new ...
- From cataracts to macular degeneration: Age-related eye problems and how to treat themon November 14, 2019 at 6:23 am
It is also necessary to ensure that the retina is in good health, otherwise the final result will not be very good. This is particularly the case for Monique, who also has the onset of age-related ...
- Age-related macular degeneration (AMD) may affect 77 million Europeans by 2050on November 12, 2019 at 1:55 pm
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in adults who are more than 50. A new study revealed that the condition might affect 77 million Europeans come ...
- Age-related macular degeneration Industry – Treatment, Outlook, Analysis, Research, Review to 2023on November 12, 2019 at 3:09 am
Age-Related Macular Degeneration (AMD) is a condition that affects the back of the eye called the macula. AMD is described as either dry or wet AMD. Age-related macular degeneration causes progressive ...
- Age related macular degeneration to affect 77 million Europeans by 2050on November 11, 2019 at 3:31 pm
The leading cause of irreversible blindness and severely impaired eyesight—age related macular degeneration, or AMD for short—is expected to affect 77 million Europeans by 2050, reveal the latest ...
- Wet Age-Related Macular Degeneration Market by...on November 11, 2019 at 1:20 pm
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
- Macular Degeneration Treatment Market Dynamics, Forecast, Analysis and Supply Demand 2019-2025on November 11, 2019 at 2:21 am
According to the American Academy of Ophthalmology, in the U.S. the age-related macular degeneration (AMD) is the major cause of severe central visual insight loss in people over the age of 50. Thus, ...
- Age-related macular degeneration — there's a shot for thaton November 9, 2019 at 8:43 am
Shingles prevention? There’s a shot for that. Syphilis? There’s even a shot for that. Macular degeneration? There’s a shot for that, too…but hold the phone…how can that be? Let’s back up and review.
- Column: Are therapies for bladder cancer and macular degeneration compatible?on November 7, 2019 at 8:07 am
This drug has proven to be useful in some cancers, which cannot grow without adequate blood supply, and in wet age-related macular degeneration, where new blood vessels in the retina are the problem.
via Bing News